نتایج جستجو برای: sustained virologic response

تعداد نتایج: 1043902  

Journal: :Journal of the Formosan Medical Association = Taiwan yi zhi 2009
Gianni Testino

Sir, I have read the excellent paper by Shifflet and Wu.1 Watanabe et al reported that several metabolic disturbances, such as obesity, insulin resistance, and hepatic steatosis, are significant risk factors for decreased sustained virologic response to interferon and ribavirin combination antiviral therapy in chronic hepatitis C patients.2 It should be noted, for completeness, the influence of...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013
Amanda Carlson Zachery Gregorich Rob Striker

Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.

Journal: :The New England journal of medicine 2014
Nassim Kamar Jacques Izopet Simona Tripon Michael Bismuth Sophie Hillaire Jérôme Dumortier Sylvie Radenne Audrey Coilly Valérie Garrigue Louis D'Alteroche Matthias Buchler Lionel Couzi Pascal Lebray Sebastien Dharancy Anne Minello Maryvonne Hourmant Anne-Marie Roque-Afonso Florence Abravanel Stanislas Pol Lionel Rostaing Vincent Mallet

BACKGROUND There is no established therapy for hepatitis E virus (HEV) infection. The aim of this retrospective, multicenter case series was to assess the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV viremia. METHODS We examined the records of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients, 10 liver-transp...

2013
Jannie Pedersen Tanja B. Jensen Thomas H. R. Carlsen Kristian Schønning Peer Brehm Christensen Alex Lund Laursen Henrik Krarup Jens Bukh Nina Weis

The correlation of neutralizing antibodies to treatment outcome in patients with chronic hepatitis C virus (HCV) infection has not been established. The aim of this study was to determine whether neutralizing antibodies could be used as an outcome predictor in patients with chronic HCV, genotype 1, infection treated with pegylated interferon-α and ribavirin. Thirty-nine patients with chronic he...

Journal: :The New England journal of medicine 2009
John G McHutchison Gregory T Everson Stuart C Gordon Ira M Jacobson Mark Sulkowski Robert Kauffman Lindsay McNair John Alam Andrew J Muir

BACKGROUND Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies. METHODS We randomly assigned patients infected with HCV genotype 1 to one of three telaprevir groups or to the c...

Journal: :Hemodialysis international. International Symposium on Home Hemodialysis 2014
Nezam Afdhal Stefan Zeuzem Paul Kwo Mario Chojkier Norman Gitlin Massimo Puoti Manuel Romero-Gomez Jean-Pierre Zarski Kosh Agarwal Peter Buggisch Graham R Foster Norbert Bräu Maria Buti Ira M Jacobson G Mani Subramanian Xiao Ding Hongmei Mo Jenny C Yang Phillip S Pang William T Symonds John G McHutchison Andrew J Muir Alessandra Mangia Patrick Marcellin

BACKGROUND In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection. METHODS We conducted a phase 3, open-label study involving previously untreated patients with chro...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007
Caroline M Behler Eric Vittinghoff Feng Lin Raymond T Chung Marion G Peters Gregory K Robbins Paul A Volberding

BACKGROUND This study investigates whether dose modifications for adverse hematologic effects or the use of hematopoietic growth factors influenced the outcome of therapy for hepatitis C virus (HCV) infection in patients who were coinfected with HCV and human immunodeficiency virus (HIV) and who were participants in a randomized, controlled trial. METHODS Subjects were randomized to receive r...

آقاصادقی, محمدرضا, دانشور, مهتاب, سادات, سید مهدی, مهمازی , ساناز,

Background and purpose: The standard of care treatment for infected patients with HCV is based on a combination of pegylated interferon alpha and ribavirin. Recently, the rs12979860 SNP polymorphism, located upstream of the interleukin 28B gene, was shown to be strongly associated with response to anti-HCV therapy. This study investigated the distribution of the (C/T) polymorphism with sust...

Journal: :Journal of hepatology 2015
Jacob Lalezari J Greg Sullivan Peter Varunok Edward Galen Kris V Kowdley Vinod Rustgi Humberto Aguilar Franco Felizarta Barbara McGovern Martin King Akshanth R Polepally Daniel E Cohen

BACKGROUND & AIMS Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates of initiation and completion of interferon-based therapies. This study evaluated efficacy, safety, and pharmacokinetics of a 12-week all-oral regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir+ribavirin in HCV genotype 1-infected patients on stable opioid replacement therapy. ...

Journal: :hepatitis monthly 0
bruno cacopardo department of clinical and molecular biomedicine, division of infectious diseases, university of catania, italy +39-0957598443, [email protected]; department of clinical and molecular biomedicine, division of infectious diseases, university of catania, italy +39-0957598443, [email protected] marilia rita pinzone department of clinical and molecular biomedicine, division of infectious diseases, university of catania, italy +39-0957598443, [email protected] filippo palermo department of clinical and molecular biomedicine, division of infectious diseases university of catania, italy giuseppe nunnari department of clinical and molecular biomedicine, division of infectious diseases, university of catania, italy +39-0957598443, [email protected]; department of microbiology and immunology, jefferson medical college, thomas jefferson university, usa

background il-33 is a novel member of the il-1 family, which has been shown to play an important role in t helper 2 (th2)-associated immune responses. recent studies have suggested a possible role for il-33 in the pathogenesis of liver damage during acute and chronic hepatitis; furthermore, il-33 may be involved in the development and progression of liver fibrosis. objectives to evaluate serum ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید